BioSpace News Archive

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:00 am ET.

Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, announced its financial results for the second quarter of fiscal 2022 ended December 31, 2021.

Aeglea BioTherapeutics, Inc. announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced that it will release financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that it intends to offer and sell in an underwritten public offering up to $200 million of shares of its common stock.

Aurinia Pharmaceuticals Inc. announced that it will release its fourth quarter and year end 2021 financial results on Monday, February 28, 2021, before markets open.

Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model.

Siolta Therapeutics today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Disease.

The financing will support further clinical trials of its lead product, FibroFix™, at Southmead Hospital Bristol, UK and in Budapest, Hungary.

Bringing together more than 1,200 attendees both in-person and virtually, MDA leads the way as the only voluntary health organization in the neuromuscular disease space to combine the latest in research, clinical care, treatment and management, with the goal of transforming care through innovation and allowing people living with neuromuscular disease to live longer lives. [09-February-2022]